Goldman Sachs Future Health Care Equity ETF (GDOC) Valuation
GDOC valuation today
Holdings combined · company data as of Oct 26, 2026- P/E (TTM)
- 76.3 trailing earnings
- Forward P/E
- 23.6 analyst estimates
- Price / sales
- 2.94
- Price / book
- 8.19
- EV / EBITDA
- 10.7
- Earnings yield
- 1.31% inverse of P/E
- Dividend yield
- 0.77% of the holdings
- Return on equity
- 10.7% combined
- Net margin
- 3.8% combined
- Beta
- 0.74 weighted, vs S&P 500
GDOC valuation vs other stock ETFs
| ETF | P/E | Fwd P/E | P/S | P/B | Div. yield | ROE | Net margin | Loss-makers |
|---|---|---|---|---|---|---|---|---|
| GDOC | 76.3 | 23.6 | 2.94 | 8.19 | 0.77% | 10.7% | 3.8% | 23.2% |
| SPY | 25.9 | 19.9 | 3.67 | 5.47 | 1.08% | 21.1% | 14.2% | 1.9% |
| QQQ | 34.2 | 23.4 | 5.93 | 9.27 | 0.58% | 27.1% | 17.4% | 6.9% |
| DIA | 20.9 | 18.4 | 3.16 | 5.52 | 1.55% | 26.4% | 15.1% | 0.0% |
| VTI | 28.2 | 19.4 | 3.31 | 5.00 | 1.07% | 17.7% | 11.8% | 4.6% |
| IWM | n/m | 13.9 | 1.25 | 2.03 | 1.38% | −1.7% | −1.0% | 28.1% |
Same method for every fund. n/m = not meaningful (combined trailing earnings below zero or close to it). Loss-makers = weight of holdings with negative trailing earnings.
GDOC valuation by sector
| Sector | Weight | P/E | Fwd P/E | P/S | P/B | Div. yield | ROE |
|---|---|---|---|---|---|---|---|
| Healthcare | 99.2% | 76.3 | 23.6 | 2.94 | 8.19 | 0.77% | 10.7% |
GDOC earnings yield vs bond yields
Earnings yield = earnings ÷ price (1 ÷ P/E). The gap to bond yields is a rough gauge of the extra return stocks are priced to deliver.
How GDOC weight splits by P/E
Share of the covered weight in companies with a trailing P/E in each range.
GDOC largest holdings: valuation
| Symbol | Company | Weight | P/E | Fwd P/E | P/S | Div. yield | Share of earnings |
|---|---|---|---|---|---|---|---|
| LLY | Eli Lilly and Company | 13.81% | 42.2 | 24.4 | 14.1 | 0.55% | 27.38% |
| MRK | Merck & Co., Inc. | 6.99% | 115.8 | 15.3 | 5.4 | 2.33% | 5.05% |
| UNH | UnitedHealth Group Incorporated | 6.04% | 25.8 | 16.6 | 0.8 | 2.31% | 19.59% |
| JNJ | Johnson & Johnson | 5.83% | 38.8 | 21.0 | 6.2 | 2.10% | 12.57% |
| VRTX | Vertex Pharmaceuticals Incorporated | 4.15% | 28.9 | 24.1 | 10.1 | — | 12.01% |
| A | Agilent Technologies, Inc. | 3.81% | 34.1 | 23.9 | 6.6 | 0.59% | 9.35% |
| TMO | Thermo Fisher Scientific Inc. | 3.76% | 37.1 | 24.2 | 5.5 | 0.27% | 8.46% |
| GH | Guardant Health, Inc. | 3.51% | — | — | 18.0 | — | −6.48% |
| EW | Edwards Lifesciences Corporation | 3.38% | 51.5 | 25.6 | 7.7 | — | 5.49% |
| DXCM | DexCom, Inc. | 3.25% | 34.1 | 28.2 | 6.5 | — | 7.96% |
| GILD | Gilead Sciences, Inc. | 3.08% | — | 15.6 | 6.4 | 2.10% | −4.38% |
| LONN | Lonza Group AG | 3.07% | — | — | — | — | — |
| NTRA | Natera, Inc. | 2.82% | — | — | 20.9 | — | −0.81% |
| COR | Cencora | 2.77% | 25.3 | 15.7 | 0.2 | 0.70% | 9.17% |
| ISRG | Intuitive Surgical, Inc. | 2.73% | 48.9 | 33.3 | 13.7 | — | 4.66% |
| ROIV | Roivant Sciences Ltd. | 2.61% | — | — | 3,215.5 | — | −3.46% |
| VEEV | Veeva Systems Inc. | 2.29% | 50.9 | 30.2 | 14.5 | — | 3.76% |
| AZN | AstraZeneca PLC | 2.17% | — | — | — | — | — |
| MTD | Mettler-Toledo International Inc. | 2.07% | 36.6 | 28.5 | 7.9 | — | 4.74% |
| RGEN | Repligen Corporation | 2.06% | 240.3 | 67.1 | 14.2 | — | 0.72% |
| RPRX | Royalty Pharma plc | 1.78% | 32.4 | 29.4 | 13.9 | 1.54% | 4.58% |
| ABBV | AbbVie Inc. | 1.50% | 80.6 | 16.4 | 7.8 | 2.42% | 1.55% |
| GALD | Galderma Group N | 1.50% | — | — | — | — | — |
| BSX | Boston Scientific Corporation | 1.46% | 18.0 | 13.2 | 3.1 | — | 6.81% |
| DGX | Quest Diagnostics Incorporated | 1.42% | 24.6 | 19.5 | 2.2 | 1.46% | 4.81% |
Share of earnings = the holding's part of the fund's combined trailing profit. Green: earns more than its weight; orange: less. Symbol links go to each company's key metrics.
About GDOC valuation
Adding up its 35 holdings with company data, GDOC trades at 76.3 times trailing earnings and 23.6 times analysts' forward estimates, with a price-to-book ratio of 8.19 and a dividend yield of 0.77%. Its earnings yield of 1.31% is 4.02 percentage points below the 5.33% yield to maturity of the U.S. bond market (AGG).
The ten largest holdings are 54.5% of the fund and earn 101.4% of its combined profit. Companies that lost money over the past year are 23.2% of the covered weight.
How these figures are calculated. Each ratio treats the fund as one company: the earnings, sales and book value of every holding are added up in proportion to its weight and divided into the fund's price. In practice that is a weighted harmonic mean, so a single stock with a very high P/E cannot distort the result, and loss-making companies reduce the fund's earnings instead of being dropped. Covers 92.0% of the fund's weight (U.S.-listed stocks with company data); company figures as of October 26, 2026.
Related: GDOC chart, GDOC performance, GDOC holdings, GDOC dividends.
GDOC valuation FAQ
What is the P/E ratio of GDOC?
Based on its holdings, GDOC has a trailing P/E of 76.3 and a forward P/E of 23.6 (earnings of all covered holdings combined in proportion to their weights, as of October 26, 2026).
What is the earnings yield of GDOC?
The trailing earnings yield is 1.31% (1 ÷ P/E) and the forward earnings yield 4.24%. For comparison the U.S. bond market (AGG) yields 5.33% to maturity and T-bills about 3.91%.
Is GDOC more expensive than the S&P 500?
GDOC trades at 76.3 times trailing earnings versus 25.9 for the S&P 500 (SPY); on forward estimates the figures are 23.6 and 19.9.
What is the price-to-book ratio of GDOC?
The holdings of GDOC trade at 8.19 times book value, with a combined return on equity of 10.7%.